Skip to main content
Figure 4 | Breast Cancer Research

Figure 4

From: Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study

Figure 4

Analysis of serum biomarker levels at baseline and at surgery, by pathologic complete response status. (A) sHER2, (B) amphiregullin, (C) EGF, (D) TGFα. (n = 112 for pCR (responders) and n = 56 for residual disease (RD) (nonresponders)) (in the box plot, the horizontal line represents the median value, the diamond represents the mean, the upper and lower bounds of the box represent the 75th and 25th quartiles, respectively, and whiskers represent 95% confidence limits). EGF, epidermal growth factor; pCR, pathological complete response; (s)HER2, (serum/shed) human epidermal growth factor receptor 2; TGFα, transforming growth factor alpha.

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us